Vagifem

Vagifem is a brand name of estradiol topical, approved by the FDA in the following formulation(s):

VAGIFEM (estradiol - tablet; vaginal)

• 
  Manufacturer: NOVO NORDISK INC
  
  Approval date: November 25, 2009
  
  Strength(s): 10MCG ^[RLD]

Has a generic version of Vagifem been approved?

No. There is currently no therapeutically equivalent version of Vagifem available.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Vagifem. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

• 
  Hormone composition
  Patent 7,018,992
  Issued: March 28, 2006
  Inventor(s): Koch; Karen & Kvorning; Ingelise
  Assignee(s): Novo Nordisk A/S
  Twice weekly administration of an analog to a Vagifem tablet which only contains 10 μg of active material has a sufficient effect.
  
  Patent expiration dates:
  
  
  • September 17, 2022
    
    ✓ 
    Patent use: TREATMENT OF ATROPHIC VAGINITIS DUE TO MENOPAUSE
  
  

Related Exclusivities

Exclusivity is exclusive marketing rights granted by the FDA upon approval of a drug and can run concurrently with a patent or not. Exclusivity is a statutory provision and is granted to an NDA applicant if statutory requirements are met.

• Exclusivity expiration dates:
  • November 25, 2012 - USE OF VAGIFEM 10 MCG FOR THE TREATMENT OF ATROPHIC VAGINITIS DUE TO MENOPAUSE
  
  

See also...

• Vagifem local Consumer Information (Cerner Multum)
• Estradiol Cream Consumer Information (Wolters Kluwer)
• Estradiol topical Consumer Information (Cerner Multum)
• Estradiol vaginal local Consumer Information (Cerner Multum)